Riverview Bio

Riverview Biosciences is a privately held biotechnology company based in South San Francisco, California, focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). Founded by a veteran leadership team with a proven track record at companies like Receptos and Gossamer Bio, the company leverages a proprietary platform to address high-value targets in immunology, inflammation, and oncology. Riverview aims to create next-generation medicines that overcome the limitations of existing GPCR-targeted therapies. The company is backed by prominent life science investors, including ARCH Venture Partners and Foresite Capital. Currently in the pre-clinical stage, Riverview is advancing a pipeline of internal programs designed to modulate GPCR signaling with high precision.